1. Introduction
Clinical motivation: Cardio-oncology is an emerging multi-disciplinary field that investigates the onset and progression of myocardial injury induced in cancer patients by chemo-therapeutic or molecular agents, as well as radiation therapy [
1]. Among the FDA-approved anthracyclines, doxorubicin (DOX) hydrochloride is one of the most effective chemotherapeutic drugs prescribed in the treatment of breast cancer [
2]. DOX has been also used in the treatment of bladder cancer, lymphoma (Hodgkin and non-Hodgkin), Kaposi’s sarcoma, and acute lymphocytic leukemia, as well as metastatic cases (e.g., gastric cancer, ovarian cancer, neuroblastoma). However, despite the therapeutic benefit offered by DOX, preclinical and clinical studies have increasingly reported progressive heart dysfunction as a critical adverse consequence of DOX-based treatments [
3,
4]. Furthermore, pharmacological studies showed that while DOX therapy induces cell death and cancer regression, it also triggers a problematic mechanism associated with cardiotoxicity based on a cascade of events that includes reactive oxidative stress [
5] and modulation of mitochondrial function [
6].
While the mechanism of cardiotoxicity remains somewhat controversial, it has been demonstrated that the cardiotoxic effects in myocytes and endothelial cells are primarily dose-dependent, leading to long-term irreversible damage of remodeled tissue, abnormal excitation–contraction coupling, and inefficient blood pumping. These major ventricular function impairments have been attributed to a gradual deposition of reactive collagenous fibrosis, causing cardiovascular complications such as cardiomyopathy or congestive heart failure and leading to collateral mortality in cancer survivors [
1,
2]. For decades, clinical studies have documented such cardiotoxic effects induced by anthracyclines only in late chronic stages, that is, after cardiomyopathy, heart failure and lethal events had occurred. Some recent investigations have focused on studying biological and physiological consequences in acute and subacute phases following chemotherapy, suggesting that both apoptosis and edema (i.e., fluid accumulation) occur within a time window of days and weeks post-DOX. In contrast, the irreversible myocardial damage, which is primarily represented by a gradual deposition of reactive fibrosis due to increased deposition of extracellular matrix (ECM), is believed to occur in sub-chronic and later phases following chemotherapy [
1,
2,
3,
4]. Moreover, only a limited number of clinical studies have related arrhythmia to cardiotoxicity in cancer survivors as a suspected causation of abnormal heart rhythms post-chemotherapy, despite the fact that these aberrant rhythms can degenerate into potentially lethal events such ventricular fibrillation [
7].
1.1. Image-Based Methods to Evaluate Chemotherapy-Induced Cardiotoxic Effects
Clinical protocols and diagnostic methods routinely use echocardiographic imaging and have reasonable sensitivity and specificity in comprehensively monitoring and detecting DOX-mediated functional changes [
8], while biopsy sampling is invasive and sparse, often missing structurally damaged tissue. Thus, the irreversible injury evolves undetected, worsening in time and leading, within months and years, to cardiomyopathy, and eventually to heart failure. Therefore, there has been a critical need to develop more accurate methods to detect earlier the cardiotoxic effects in sub-chronic phases following DOX-based therapies. With this respect, MR imaging offers excellent tissue contrast. For example, one group recently utilized MRI to assess cardiotoxicity in breast cancer survivors, showing that most patients had significantly different values of ejection fraction and global strain post-DOX compared to the baseline, and some presented evidence of diffuse fibrosis [
9]. While 2D Cine and Late Gadolinium Enhancement methods are able to characterize post-DOX functional and structural changes [
9], these scans typically use protocols with large slice thickness (~8–10 mm), similarly to those in acute or chronic infarct scars [
10]. Current T1 and T2 mapping methods can differentiate, overall, the injured myocardium post-chemotherapy [
11]; however, these low-resolution images (voxel size 2 × 2 × 10 mm
3) might miss subtle structural alterations. Thus, advanced methods using high-resolution 3D imaging should be adapted for imaging protocols of post-DOX evaluation.
1.2. Role of Pre-Clinical Animal Models of Cardiotoxicity
Animal models of cardiotoxicity represent a reasonable alternative to clinical investigations, allowing us to perform detailed and controlled studies that can address unanswered clinical questions. For example, image-based longitudinal studies in animals can reveal new biomarkers of adverse myocardial remodeling at different time points following DOX therapy, improving our mechanistic understanding regarding reversible vs. irreversible effects. Such models can be used to test more effective cardioprotective strategies prior to implementation in clinical trials. Furthermore, compared to sparse in vivo biopsy sampling, animal models hold the great advantage of allowing us to study the entire heart after explantation for the purpose of histopathological assessment.
With respect to this, a large body of literature has reported the development of pre-clinical models of chemotherapy-induced cardiotoxicity. Many chronic models using small animals (e.g., mice [
12], rabbits [
13], mini-pigs [
14]), have clearly demonstrated that the severity of structural myocardial remodeling is dependent on the cumulative dose of the chemotherapeutic drug, leading to mechanical dysfunction with poor ejection fraction and progressive heart failure. Unfortunately, small animal models are less relevant to the clinical translation of diagnostic imaging methods. Thus, more recently, one research group developed a swine model of cardiotoxicity and used MR imaging to demonstrate that the prolongation of T2 parameter (indicating edema) is reversible in early stages post-DOX, and that the LV function declines gradually within the first few months post-DOX [
15]. However, in this study, DOX was administered intracoronary through a catheter, an invasive procedure which does not mimic the chemotherapeutic plan in patients. Therefore, alternative delivery methods, such as the intravenous injection of doxorubicin (as done in patients), might be more realistic to study cardiotoxicity in large animal models.
The specific aims of our work here are: (1) to develop a translational swine model to study DOX-induced cardiotoxicity, precisely mimicking the intravenous delivery of doxorubicin in cancer patients; and (2) to establish subtle quantitative MR imaging features and electrophysiological characteristics of DOX-induced cardiotoxic effects in the sub-chronic phases post-DOX (i.e., weeks and a couple of months after the DOX treatment was ceased). Specifically, in this preclinical work, we propose an MR imaging protocol that allows us to monitor, post-DOX, the temporal evolution of the left ventricular function (i.e., via Cinematic methods) and of the structural alterations (i.e., using high-resolution 3D contrast-enhanced MR to detect deposition of collagenous fibrosis), along with histological validation. In addition, our novel experimental protocol includes a complex X-ray-guided electrophysiological study to evaluate endocardial bipolar voltage maps and arrhythmia inducibility following the completion of DOX treatment.
2. Methods
All preclinical animal experiments were approved by the research ethics board of the Animal Care Committee at our Sunnybrook Research Institute (Toronto), and the DOX-related procedures were performed while ensuring all biohazard safety requirements.
The design of the experimental animal study to evaluate DOX-induced cardiotoxicity included the following: DOX treatment delivered weekly via intravenous injection; functional and structural MRI imaging (pre-DOX and post-DOX delivery) and associated image analysis; X-ray guided electrophysiology studies (voltage mapping and arrhythmia inducibility); and, lastly, histological staining of select myocardial tissue samples. The associated pipeline of our research protocol is illustrated in
Figure 1, where each component is described in more detail below.
2.1. Development of a Preclinical Large Animal Model to Study DOX-Induced Cardiotoxicity
In this work, we used n = 4 juvenile healthy Yorkshire swine, weighing 20–25 kg prior to the commencement of DOX injections. Note that an additional healthy swine was used as control for the electrophysiology studies and histological validation. The dosage of doxorubicin (i.e., 1 mg/kg) was given based on the pig’s weight, as per the typical chemotherapeutic doses. For each delivery, DOX was diluted into a 100 mL bag of saline and administered intravenously (i.v.) either into the ear or using a vascular access port (VAP) designed for large animals. The DOX solution was slowly injected over a 20–30 min period. The four pigs receiving DOX treatment were split into 2 groups: (i) Group 1 (pig #1 and pig #2, respectively), sacrificed at 5 weeks post-DOX; and (ii) Group 2 (pig #3 and pig #4, respectively), sacrificed at 9 weeks post-DOX. This grouping was carried out to enable the validation of longitudinal observations at two time points vs. histology.
2.2. In Vivo MR Imaging Protocol and Associated Analysis
MR imaging studies were conducted on a 3T whole body scanner (MR 750, General Electric Healthcare, Waukesha, WI, USA). Prior to imaging (
Figure 2a), each animal was sedated using an anesthetic mixture of atropine (0.05 mg/kg) and ketamine (30 mg/kg), and was supported through mechanical ventilation. Anesthesia was maintained with isoflurane/O
2 (1–5%). For image acquisition, an 8-channel cardiac anterior array coil was placed on each pig. The heart rate and associated physiological signals were continuously monitored. The proposed MR imaging protocol presented in this paper included: a short-axis 2D CINE sequence for heart function evaluation, as well as a high-resolution 3D late gadolinium enhancement (LGE) for the identification and quantification of fibrosis. Amiodarone was injected in order to avoid arrhythmic events during the MR imaging study, which kept the heart rate stable and below 100 bpm. The heart rate stabilization improved image acquisition process and, consequently, the quality of reconstructed images.
As per the diagram previously presented in
Figure 1, the MR images were acquired at the following time points: (a) at baseline healthy state (pre-DOX injections) in both groups; (b) at one week after the completion of DOX injections in all four animals; (c) at five weeks post-DOX injections in Group 1 (i.e., in pig #1 and pig #2, respectively), and (d) at nine weeks post-DOX injections in Group 2 (i.e., in pig #3 and pig #4, respectively).
For the assessment of cardiac function, we utilized a steady-state free precession (SSFP) sequence in Cine mode, with the following MR parameters: 16–20 short-axis slices to cover the entirety of the heart (prescribed on longitudinal-axis images, as in
Figure 2b), 8 views/segment, 20 cardiac phases/slice, repetition time TR= 4.2 ms, echo time TE = 1.8 ms, flip angle = 45°, matrix size = 224 × 160, in-plane resolution of 1 mm × 1 mm, and slice thickness = 5 mm (with no gap between slices). All Cinematic images were acquired using ECG- gating and breath holds.
Contrast-enhanced imaging was performed by employing a free-breathing 3D late gadolinium enhancement (LGE) method, approximately 5–6 min after injecting a bolus of gadolinium-based contrast agent Gd-DTPA (0.2 mmol/kg, Magnevist, Bayer Healthcare Pharmaceuticals, Berlin, Germany). The 3D LGE method with isotropic voxels size was based on a 3D inversion recovery fast gradient echo (IR-FGRE) sequence with fat suppression and respiratory navigation (initial inversion time TI = 300 ms, repetition and echo times TR/TE = 3.5/1.5 ms, bandwidth BW = 100 kHz, flip angle = 15°, and an isotropic spatial resolution of 1.4 mm × 1.4 mm × 1.4 mm), similarly to the method we previously used in preclinical MR imaging studies to evaluate chronic infarct scars [
16].
2.3. MR Image Analysis
First, the Cine images were analyzed with the CVI42 software (Circle Cardiovascular Imaging, Calgary) [
17], to assess left ventricular function. The endocardial and epicardial contours were semi-automatically delineated, and then corrected by a clinical expert (cardiologist I.R.). Using these contours, we derived the end-systolic and end-diastolic volumes (ESV and EDV, respectively). The ejection fraction (EF) functional parameter was then calculated with the well-known formula: EF(%) = (EDV − ESV)/EDV, for each dataset (i.e., each time-point), allowing us to observe the longitudinal changes over the weeks following the completion post-DOX delivery.
Second, the LGE images were analyzed using in-house custom scripts written in Matlab (Mathworks, Torrance, CA, USA), according to the image analysis pipeline illustrated in
Figure 3. Briefly, for each raw MR image, we first performed manual endocardial and epicardial contouring of the LV. A region of interest (ROI) was selected from the remote myocardium on the posterior side. Subsequently, pixel-wise maps of signal intensity within the segmented LV were used as input to an algorithm able to differentiate healthy myocardium vs. fibrotic pixels based on a simple signal intensity thresholding method.
Specifically, in order to cluster the pixels into the two distinct regions (i.e., fibrosis and healthy tissue), we used a 5 standard deviation (SD) threshold for signal intensity, which is clinically accepted for fibrosis assessment [
18]. Moreover, the LV binary masks were used to calculate the LV volume for each heart. At each time-point, for each heart, the density of fibrosis (%) was calculated as the ratio between the fibrosis volume (derived from the total number of segmented fibrosis voxels in each LV) and the LV volume.
2.4. Electrophysiology Studies (Mapping and Arrhythmia Test)
The day following the imaging studies at 9 weeks post-DOX, catheter-based electro-anatomic mapping (EAM) and an arrhythmia inducibility test were performed in pigs #3 and #4, respectively. An additional EAM study and arrhythmia test was performed in a healthy (control) pig. All animals were intubated and sedated, and anesthesia was maintained throughout these EAM procedures using the same combination of medications as those administered prior to the MR imaging scans. However, amiodarone was not administered, since one objectives of the EP study was to evaluate arrhythmia inducibility.
All three interventional electrophysiology EP studies were carried out under X-ray guidance, using a C-arm Toshiba INFINIX VF-I/SP-S (
Figure 4a). Catheter-based EAM of the left ventricular (LV) endocardial surface was performed in these animals by employing a conventional CARTO3 electrophysiology system (Biosense Webster Inc, Diamond Bar, CA, USA). For the endocardial mapping procedures, we used a PentaRay
® catheter (Biosense Webster Inc., Irvine, CA, USA) inserted into the LV cavity, via femoral access.
The EAMs were primarily acquired for the purpose of constructing detailed bipolar voltage maps (i.e., more than one thousand points per map, in sinus rhythm and under pacing conditions). The bipolar voltages characterized by low amplitude values (0.1–1.5 mV) were attributed to patches of fibrotic tissue, whereas the areas with an amplitude voltage > 1.5 mV were considered normal, in accordance with the clinical threshold typically used to define scarred tissue [
19]. The low bipolar voltage areas were qualitatively compared to those defined by LGE using ADAS 3D software, version 2.11.1-beta.2 (
www.adas3D.com, accessed on 31 October 2022). Several representative points that had low voltage values (denoting fibrosis) were selected for a qualitative evaluation of the QRS and QRS-T intervals.
For the arrhythmia inducibility test, we inserted an SF Thermocool catheter (Biosense Webster Inc., Irvine, CA, USA) into the right ventricle (RV) and performed rapid pacing of the heart.
Figure 4b shows an exemplary X-ray image of the heart during the EP study (in pig #3), with the pacing catheter inside the RV and the mapping catheter (with 5 prongs and multiple sensors on each prong) inside the LV. The external ECGs placed onto the animal torso for reference, are also visible.
2.5. Histology
Except for pigs #3 and #4 (in which death was caused by VF), the other three animals were euthanized as per the approved protocol. All five hearts were carefully explanted, then fixed and preserved in formaldehyde solution for at least 1 week in order to ensure a uniform preservation of tissue. Tissue samples were collected from each heart and select cross-sections (i.e., slices cut at 4 mm thickness) corresponding to short-axis MR images (as guided by anatomical landmarks) were cut at 4 µm thickness. These were mounted on large glass slides and stained with collagen-specific Mason Trichrome stain to visualize the deposition of collagenous/reactive fibrosis. Following staining, the slides were digitally scanned using a special TissueScope (Huron Technologies, St. Jacobs, ON, Canada) that accommodates large pathology slides. These digital images were visualized using Aperio ImageScope [
20], an open-source software specifically designed for pathological evaluation of digital images.
2.6. Statistical Analysis
Since this is a methodological protocol paper with the animal model being tested only in a small pilot study, the study was not powered statistically. Therefore, we focused on qualitative analyses and highlighting the longitudinal evolution of individual parameters (EF and fibrosis density) per animal.
4. Discussion
Accurate identification of characteristics specific to reversible and irreversible myocardial remodeling post-chemotherapy could help clinicians to assess the long-term effects of DOX therapy and to predict the risk of sudden cardiac death associated with heart failure [
21]. A major role in the identification of early cardiotoxic signs (weeks and months post-DOX) can be played by cardiac imaging. Among the various imaging methods nowadays available to characterize cardiac function [
22] and structure [
9,
11], MR imaging may soon be the preferred technique for evaluating myocardial injury post-chemotherapy [
23], owing to its robust imaging sequences and excellent tissue contrast.
In this work, we demonstrated the feasibility of a large animal (swine) model to explore functional and subtle structural cardiotoxic changes induced by DOX. As a first novel aspect of our protocol, in distinction to the catheter-based intracoronary delivery employed by other researchers in pig models [
14,
15], in our pilot study, we successfully used non-invasive intravenous (i.v.) injections of DOX, similarly to the clinical chemotherapeutic approaches. Our histologically validated results clearly demonstrated that reactive fibrosis occurred as a side-effect of the DOX treatment within the first couple of months, following the completion of one 4-week cycle of treatment. The deposition of fibrosis appeared to lead to an irreversible ventricular mechanical dysfunction, although we acknowledge that a monitoring period longer than 9 weeks could better support this observation. With this respect, we suggest that future studies could replace the Yorkshire swine with Yucatan pigs, since the latter animals do not gain weight (in time) and therefore they could better fit in the relatively narrow bore of 3T MR scanners.
A second novel aspect is related to the identification of scattered pixels of fibrosis in the high-resolution 3D LGE images. Compared to clinical 2D MR scans that typically use 8–10 mm slice thickness, our 3D LGE method is superior in overcoming issues associated with partial volume effects, which are problematic particularly in the setting of diffuse fibrosis. Furthermore, our Cine and LGE MR imaging methods are both superior, in terms of spatial resolution, to those used in other preclinical DOX studies. For example, for functional imaging, our voxel size was 1 mm × 1 mm × 5 mm= 5 mm
3 (which is four times smaller than the voxel size of 1.8 mm × 1.8 mm × 6 mm = 19.6 mm
3 used by Galán-Arriola et al. in [
15]). For the LGE method, we used a voxel size of 1.4 mm × 1.4 mm × 1.4 mm = 2.74 mm
3, which is smaller compared to the ~3.75 mm
3 voxels used in [
15]. The higher the spatial resolution is, the less significant the partial volume effects are; thus, we suggest that our MR imaging methods may provide more accurate functional parameters and structural information. Moreover, the authors of ref. [
15] only presented raw LGE images, without specifically identifying the fibrotic pixels using clinically accepted algorithms as in our study.
Our free-breathing, high resolution 3D LGE method appears more adequate for pixel-wise quantitative analysis of collagen density than the 2D T1 mapping images acquired at 5 mm slice thickness [
24]. However, LGE imaging is known to be sensitive to contrast injections, and the image analysis based on 5SD threshold is user-dependent (i.e., with respect to the selected ROIs), while T1 mapping techniques are more robust [
25]. Given the important role of diffuse fibrosis in post-chemotherapy [
26], our future work will focus on implementing a high-resolution 3D T1* mapping method. This method has the capability to distinguish dense collagenous fibrotic patches, as demonstrated in a previous study performed ex vivo in chronically infarcted porcine hearts [
27], and has already been translated to preclinical in vivo free-breathing 3D imaging of infarct scars, using a 1.4 mm isotropic resolution [
16]. Furthermore, in the imaging protocol, we plan to include T2-based methods to evaluate edema resorption, a reversible side-effect of DOX which we recently observed in [
24] (in three animals). Lastly, with respect to cardiac functional assessment, the gradual decline in ejection fraction observed in the current work within the first 9 weeks post-DOX indicated an early sub-acute and sub-chronic occurrence of biomechanical dysfunction, in agreement with the swine study of cardiotoxicity that used intracoronary DOX injections [
15]. We suggest that the collagen deposition has substantially contributed to the overall EF decline, and will likely have a critical role in the further evolvement towards heart failure.
Regarding the third novel aspect, to the best of our knowledge, this is the first preclinical study to report X-ray guided electro-anatomical mapping of endocardial bipolar voltages in a large animal model post-chemotherapy, as most studies have focused only on longitudinal assessment of cardiac mechanical function. The recorded intracardiac iEGM signals, acquired with a catheter-based clinical systems, revealed small patches of fibrotic tissue with reduced bipolar voltage amplitude, which is typically seen clinically in scarred myocardium post-infarction. Our findings also suggest that early electrical remodeling takes place within the first couple of months post-DOX, with prolonged QRS-T intervals accompanying the low voltages in fibrotic areas. The small patches of dense collagenous fibrosis located within areas of abnormal iEGM waves’ morphology likely created unexcitable obstacles in the electrical wave pathway, generating reentrant waves, spiral wave break, and chaotic electrical propagation. This eventually led to lethal ventricular fibrillation during the rapid pacing procedure, similarly to the scar-related ventricular arrhythmias induced in post-infarction. Future work will include the monitoring of spontaneous arrhythmia episodes via MR-compatible implantable cardioverter defibrillators, in order to study the risk of lethal arrhythmia development post-chemotherapy.
We acknowledge that one study limitation is the small number of animals. However, in this work, we aimed to describe in detail the experimental protocol and qualitative results, using a minimum number of animals for tests and respecting the ‘3Rs principle’ in animal research (i.e., replacement, reduction, and refinement). Nonetheless, we plan to expand the cohort in the future by including more animals, which will enable us to give statistical power to the study.
We envision that preclinical large animal models of cardiotoxicity will substantially help researchers better understand the mechanistic effects of cardiotoxicity. Such models can also provide a robust translational platform for testing new individual cardio-protective strategies or a synergistic combination of those [
28,
29]. These could slow the irreversible myocardial injury and associated dysfunction post-chemotherapy, and restrict further progression towards the heart failure stage. Our future work will also focus on testing 3D virtual models in order to predict the electro-mechanical function post-cardiotoxicity, integrating MRI-defined fibrosis areas and electrical remodeling information. Such in silico computer models can be exploited to virtually predict risk of arrhythmia and impaired mechanical contraction (including the EF index) [
30] either for screening of drugs’ cardiotoxicity [
31] or to design more efficient therapeutic strategies, in conjunction with information provided by early imaging biomarkers and knowledge gained from animal models of cardiotoxicity [
32].